Rohto Pharmaceutical Co.,Ltd.
4527.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | ¥31,005,000 | ¥30,937,000 | ¥34,290,000 | ¥27,953,000 |
| Dep. & Amort. | ¥13,143,000 | ¥8,687,000 | ¥7,801,000 | ¥7,673,000 |
| Deferred Tax | ¥0 | ¥0 | ¥0 | ¥0 |
| Stock-Based Comp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Change in WC | -¥6,032,000 | -¥8,856,000 | -¥11,277,000 | ¥458,000 |
| Other Non-Cash | -¥1,199,000 | ¥3,477,000 | ¥110,000 | -¥8,834,000 |
| Operating Cash Flow | ¥36,917,000 | ¥34,245,000 | ¥30,924,000 | ¥27,250,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -¥10,561,000 | -¥7,979,000 | -¥9,908,000 | -¥11,328,000 |
| Net Acquisitions | ¥31,646,000 | ¥0 | -¥1,582,000 | -¥1,203,000 |
| Inv. Purchases | -¥9,537,000 | -¥9,080,000 | -¥5,940,000 | -¥5,615,000 |
| Inv. Sales/Matur. | ¥5,974,000 | ¥1,704,000 | ¥2,641,000 | ¥1,963,000 |
| Other Inv. Act. | -¥106,692,000 | -¥962,000 | ¥1,613,000 | -¥223,000 |
| Investing Cash Flow | -¥89,170,000 | -¥16,317,000 | -¥13,176,000 | -¥16,406,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | ¥31,907,000 | -¥1,223,000 | -¥9,882,000 | ¥7,590,000 |
| Stock Issued | ¥0 | ¥0 | ¥0 | ¥0 |
| Stock Repurch. | -¥5,000,000 | ¥0 | ¥0 | ¥0 |
| Dividends Paid | -¥7,072,000 | -¥5,475,000 | -¥4,676,000 | -¥3,422,000 |
| Other Fin. Act. | ¥15,484,000 | -¥7,086,000 | -¥1,641,000 | -¥698,000 |
| Financing Cash Flow | ¥35,319,000 | -¥13,784,000 | -¥16,199,000 | ¥3,470,000 |
| Forex Effect | ¥3,374,000 | ¥4,703,000 | ¥5,236,000 | ¥4,335,000 |
| Net Chg. in Cash | -¥13,341,000 | ¥8,871,000 | ¥6,786,000 | ¥18,651,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | ¥86,562,000 | ¥77,691,000 | ¥70,905,000 | ¥52,254,000 |
| End Cash | ¥73,221,000 | ¥86,562,000 | ¥77,691,000 | ¥70,905,000 |
| Free Cash Flow | ¥27,837,000 | ¥25,333,000 | ¥21,016,000 | ¥15,922,000 |